SCHEMBL23200380

SCHEMBL23200380

Cc1ccc(S(=O)(=O)Nc2ccc(C(F)(F)F)cc2C(=O)O)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.79
METAP2 P50579 4/20 0.67
CYP1A2 P05177 1/20 0.60
CYP2C9 P11712 1/20 0.60
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
GAA P10253 1/20 0.57
ACLY P53396 2/20 0.57
FFAR1 O14842 1/20 0.55
CDK1 P06493 1/20 0.55
CCNB1 P14635 1/20 0.55
CCNA2 P20248 1/20 0.55
CDK2 P24941 1/20 0.55
CDK7 P50613 1/20 0.55
CCNH P51946 1/20 0.55
CCNA1 P78396 1/20 0.55
FFAR4 Q5NUL3 1/20 0.55
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MCL1 Q07820 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23141293 0.90 KDM1A (0.79) KDM1AMETAP2CYP1A2CYP2C9MEN1
SCHEMBL23141205 0.88 KDM1A (0.81) KDM1AMETAP2MEN1KMT2AGAA
SCHEMBL23141186 0.88 KDM1A (0.81) KDM1AMETAP2MEN1KMT2AGAA
SCHEMBL3528690 0.88 KDM1A (0.61) KDM1AMETAP2CYP1A2CYP2C9MEN1
SCHEMBL23141255 0.86 KDM1A (0.74) KDM1ACYP1A2CYP2C9MEN1KMT2A
SCHEMBL12570805 0.85 METAP2 (0.86) METAP2CYP1A2CYP2C9ACLYLMNA
SCHEMBL12200769 0.83 METAP2 (0.71) KDM1AMETAP2CYP1A2CYP2C9MEN1
SCHEMBL16496289 0.82 METAP2 (0.75) KDM1AMETAP2CYP1A2CYP2C9ACLY
SCHEMBL7383795 0.81 CYP2C9 (0.69) KDM1AMETAP2CYP1A2CYP2C9FFAR4
SCHEMBL7577221 0.81 MEN1 (0.62) KDM1AMETAP2CYP1A2CYP2C9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 US disclosed
EP-3802514-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB KDM1A 3235/4885METAP2 820/4885CYP1A2 3322/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB KDM1A 3235/4885METAP2 820/4885CYP1A2 3322/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB KDM1A 3235/4885METAP2 820/4885CYP1A2 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.